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significantly increased from 18% to 25% with carvedilol and bisoprolol versus meto-
prolol tartrate. Our primary findings were consistent through various sensitivity 
analyses. ConClusions: We suggest that there is no evidence of a differential 
effect of β -blockers on mortality in older patients with HF, but the agent selected 
may have an impact on the rate of HF readmissions.
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objeCtives: Identifying the drivers of trends in mortality for disease classes is 
challenging. We used the Requiem model to visualise trends by gender and age in 
3-D format to identify cohort effects, impacts of interventions and mortality coding 
changes in specific cardiovascular diseases (CVD). Methods: The Requiem model 
analysed and smoothed ONS mortality statistics for England and Wales from 1970 
to 2013 by single year of age and gender. Disease codes were mapped at 4-digit 
level from ICD-8 to ICD-10 by medical modellers. An analysis was run for all CVD 
and individual diseases within that category. Outputs were displayed in multiple 
formats, including 3-D images of central mortality and deaths by age over time, 
and heat maps of absolute mortality improvement per disease and the component 
each disease contributed to all-cause mortality trends. Results: CVD mortality 
has declined by up to 8% per year in England and Wales, especially in the “golden 
cohort” born in the 1930s, as shown clearly in the heat maps. Mortality rates from 
ischaemic stroke have fallen precipitously by up to 10% per year in both genders, 
especially in the 80+ age group, as shown in the 3-D charts. This contributed up to 
0.4% absolute improvement in all-cause mortality prior to 1990. Mortality improve-
ment from myocardial infarction was up to 20% per year in both genders aged 
40 to 80, especially in the mid-1980s to 1990s, contributing up to 2% in absolute 
improvement in all-cause mortality in men in the mid-1980s and 1% in women in 
the early 1990s. ConClusions: The Requiem model 3-D visualisation shows the 
substantial improvement in mortality from CVD and all causes was largely driven by 
improvements in ischaemic stroke and MI in the golden cohort. In future years, as 
this cohort eventually dies, mortality improvement rates in CVD are likely to decline.
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objeCtives: To use a stochastic all-cause, cause of death mortality model to deter-
mine the risk of cardiovascular (CVD) mortality in smokers compared with non-
smokers in the UK allowing for competing causes of death. Methods: The Sonata 
Vivo model adjusts population baseline mortality for known risk factors to calculate 
the mean age of death and most likely causes of death for an individual, and has 
been validated against long-term cohorts in the UK and USA. We used the model to 
calculate the likely outcomes for a 50 year-old male who smokes no, 10 or 20 ciga-
rettes a day, with population average values for blood pressure, body-mass index, 
cholesterol and alcohol consumption. Results: The mean ages of death were 82.7 
years for the non-smoker, 78.7 years for a 10/day and 76.1 years for a 20/day smoker. 
At each year of life, smokers had a higher mortality from CVD than non-smokers. 
However, overall, there were fewer CVD deaths in smokers than non-smokers. This is 
an example of Simpson’s paradox, where an association between factors at a popu-
lation level may be the opposite for each subgroup in the population. Smokers have 
increased mortality from cancer and respiratory disease, and on average die of these 
at a younger age than those who eventually die of CVD. Smokers also have fewer 
years of life than non-smokers in which CVD deaths can occur. ConClusions: 
Smoking increases the risk of many diseases, which have their greatest impact at 
different ages. Smokers have lower overall risks of CVD death as they are more likely 
than non-smokers to have died of cancer before the peak age for CVD deaths. The 
real-world effect of interventions for smoking-related diseases will be influenced 
by this impact of competing causes of death.
CardioVasCular disorders – Cost studies
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objeCtives: Venous thromboembolism(VTE) which comprises deep vein 
thrombosis(DVT) and pulmonary embolism(PE) is associated with a significant health-
care burden. Currently, standard of care is parenteral low molecular weight heparin 
(enoxaparin) plus warfarin. Rivaroxaban is an oral anticoagulant that doesn’t require 
dose adjustment or routine coagulation monitoring, bringing an important advan-
tage for VTE treatment. The EINSTEIN clinical program of rivaroxaban showed that, 
overall, hospitalized patients who received initial treatment with rivaroxaban for DVT 
and PE had a significantly shorter length of stay compared to patients who received 
enoxaparin/VKA. Therefore, the aim of this study was to estimate the budget impact 
of rivaroxaban treatment for VTE in comparison with current practice. Methods: 
The BIM was developed with a 1-year time horizon. Eligible patients were estimated 
for the entire private health system population and for single health plan according to 
three profiles (big, medium and small size). Epidemiology data, drug costs and adverse 
events information were obtained from literature. Resource utilization was captured 
from literature and validated by an expert panel. Total costs of hospitalization and 
14.5); ACS 12-24 months, 7.0 (95% CI 5.8-8.2); ischaemic stroke, 7.8 (95% CI 7.2-8.5); 
other CHD, 5.0 (95% CI 4.9-5.1); PAD, 6.7 (95% CI 6.4-7.1); diabetes without CVD, 1.9 
(95% CI 1.9-1.9); CKD without CVD, 6.4 (95% CI 5.9-6.9). ConClusions: This study 
suggests that CV event rates continue to remain high in the UK general popula-
tion with CVD or CKD. Patients who experienced an ACS event during the past 12 
months and those with a history of ischaemic stroke are at a particularly elevated 
risk for recurrent events.
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objeCtives: Long-Term Care (LTC) service users with dementia show higher 
expenditure and association of care-needs level (CNL) deterioration. The aim of 
this study was to determine risk factors that are associated with death among 
elderly LTC service users in Japan. Methods: In a retrospective cohort study, we 
extracted data from all subjects who used LTC services with CNL ranging from 1 
to 5 in 2010 in Kyoto prefecture, Japan. Our sample consisted of 50,268 adults aged 
65 years and above in 2010 and who had given consent to linkage of their National 
Healthcare Insurance data with corresponding LTC insurance claims data. Dementia 
and death were defined according to the corresponding ICD-10 code. Logistic regres-
sion (LR) analysis was used to identify factors associated with death in June 2011. 
Furthermore, we developed and pruned a supervised learning approach using non-
parametric Classification and Regression Tree (CART) and Random Forest (RF), the 
algorithms of machine learning, to create risk factors for death. In order to avoid 
model over fitting, we did our sampling by 1 to 1 ratio. Finally, our samples consisted 
of 12,070 adults enrolled and set 70% as training dataset, 15% as testing dataset, 
and 15% as validation dataset. Results: The factors associated with death were 
hospitalization more than 30 days in one year, older age, the male sex, and higher 
CNL, facility care services/ home care services use, and new dementia diagnosis 
with an area under the curve (AUC) of 0.782. Similar results were observed in the 
supervised learning approach, which including CART and RF for death with an AUC 
of 0.7333 and 0.7623, respectively. ConClusions: When applied prudently, both 
LR and CART are suitable for the analysis of death prediction, and more research 
is required to investigate the factors that are related to long-term hospitalization 
among elderly.
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objeCtives: Few studies examined the course of functional recovery following 
rehabilitation in patients after intracerebral hemorrhage (ICH). The prediction of 
progressive increments in functional status is important for appropriate treatment 
planning and for setting rehabilitation goals. The aim of this study was to develop 
and validate a prognostication model to predict the functional status at discharge 
for ICH patients using a retrospective cohort data in the Korea. Methods: Data 
were collected on electronic medical record (EMR) referrals and brain computed 
tomography (CT) images from the National Rehabilitation Center (NRC) in Korea. 
Functional level was measured using the modified bathel index (MBI), recorded at 
admission and discharge. Factors considered for predictors associated with the MBI 
total score at discharge included patients’ clinical and imaging variables (ICH loca-
tion, ICH volume, mass effect due to hemorrhage etc) at the admission. Results: 
Five hundred twenty six patients aged 13 years or older (mean age: 57.2 years) who 
were discharged between November 15, 2006 and April 24, 2015, from NRC were 
retrospectively followed. Predictors of the total discharge MBI score included stand-
ing balance, cognitive function measured by the total score of Mini-Mental State 
Examination (MMSE), functional ambulation categories, muscle strength of left hip 
flexor, muscle strength of right knee extensor, presence of pneumonia, spasticity of 
right lower extremity, intraventricular hemorrhage score, abnormality of pain sense, 
aphasia, hemorrhage of brainstem, intracerebral hemorrhage volume, longitudinal 
sitting balance, mass effect due to hemorrhage. The adequacy of prediction was as 
measured by adjusted R2= 0.8013. ConClusions: The functional status prediction 
model performed well. Further studies should be planned to evaluate whether the 
model can be of practical use to physicians when attempting to set up an appropri-
ate rehabilitation schedule at the patients’ admission.
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objeCtives: To compare the effectiveness of ß-blockers for older patients follow-
ing a primary hospital admission for HF. Methods: We conducted a cohort study 
using Quebec administrative databases to identify patients who were prescribed the 
ß-blockers, carvedilol, bisoprolol or metoprolol tartrate after the diagnosis of HF. We 
characterize the patients by the type of ß-blocker prescribed at discharge of their 
first HF hospitalization. To control for differences among patient characteristics, a 
multivariate Cox proportional hazards model was used to compare the combined 
primary endpoint of all-cause mortality and HF readmission, its components, and 
cardiovascular mortality. Results: Of the 3609 patients with HF with a median fol-
low-up of 3.0 years, the crude annual mortality was 16.5% with metoprolol tartrate, 
15.7% with carvedilol, and 17.7% with bisoprolol. After controlling for covariates, 
we found that carvedilol (HR 0.94; 0.80-1.09) and bisoprolol (HR 1.05; 0.94-1.17) were 
not superior to metoprolol tartrate in improving survival. HF readmission rate was 
